Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as cytarabine and idarubicin, work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving lestaurtinib together with cytarabine and idarubicin may
kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of lestaurtinib
when given together with cytarabine and idarubicin and to see how well they work in treating
younger patients with relapsed or refractory acute myeloid leukemia.